Company intelligence / Profile preview
LineaRx
Stony Brook, New York, United Stateslinearxdna.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Early data demonstrated successful expression of PCR-generated genes such as GFP in human T cells ex vivo. The anti-CD19 construct showed complete remissions in small patient cohorts when delivered via viral vectors previously; current efforts focus on replicating efficacy with nonviral linear-DNA approaches[7]. Vaccine candidates have shown tumor reduction signals preclinically[8].
- Therapeutic areas
- OncologyHematology
- Modalities
- Linear DNA constructs for gene therapy and cellular therapiesmRNA production templates via enzymatic methodsNonviral plasmid-free CAR T cell therapiesAnti-cancer vaccines based on linear-DNA platforms
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
iCell Gene TherapeuticsTakis/Evvivax
Beyond the preview
Go deeper on LineaRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LineaRx.